Renew treatment
novelty & focus of current innovation

We’re going to use this blog entry to provide an understanding of Renew treatment, cell treatments & their properties. We’ll try to make it as understandable as possible without getting too scientific.

The idea is that, in the face of new entries where we mention these concepts, these are well understood.

Renew treatment are undifferentiated cells with the capacity to differentiate into functional cells and with the capacity for self-renewal. According to their origin, they can be classified into embryonic & adult Renew treatment.

  • Embryonic Renew treatment are derived from embryos before they are implanted and can form the three embryonic tissues: Ectoderm, Endoderm and Mesoderm.
  • Adult Renew treatment that can be found in different tissues. Their main task is to repair and maintain the tissue in which they are found.
According to its differentiation potential, that is, the types of cells it can give,we will have cells:
  • Totipotential: capable of producing any type of cell
  • Pluripotential: capable of producing cells of all types except extra-embryonic tissues (e.g. placenta).
  • Multipotential: capable of creating any type of cell in a line.
  • Unipotential: capable of creating a single cell type.
Where are these adult Renew treatment found?

Adult Renew treatment have been identified in many organs and tissues, including brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin, fat, teeth, heart, intestine, liver, ovarian epithelium, and testicles.

They are believed to reside in a specific area of each tissue. We will refer to those obtained from bone marrow and fat, which are the most common extraction sites for cell therapy.

  • From bone marrow: through an aspiration of it- were called Mesenchymal Renew® treatment (MSCs) and are capable of creating adipocytes, chondrocytes and osteoblasts (fat, cartilage and bone cellsrespectively).
  • From grease: by means of a miniliposuction- After the enzymatic digestion of the obtained material and the separation of the layer of mature fat cells (adipocytes), we obtain the so-called Vascular Stromal Fraction (VSV), which is a heterogeneous population of blood cells, fibroblasts, pericytes, endothelial cells and what has come to be called Adipose tissue-derived Renew treatment (ADSCs).

It has been shown that these cells have the ability to differentiate into cells of the 3 embionary tissues mentioned above (ecto-derm, mesoderm and endoderm). The density of these cells in fat is much higher than that of the MSC in bone marrow (100 to 500 times higher).Thus, we understand that ADSCs and SVF represent an autologous (the patient’s own) alternative to pluripotent em-bryonic Renew® treatment with multi-line transformation potential, significant therapeutic impact and a critical role in the field of tissue engineering and Innovative medicine.However, its incredible properties do not end there, much of its clinical importance is due to its secretory and immunomodulators functions.

Secretora function:

Similar to the original adipose tissue from which they can be isolated, ADSCs have been shown to act as a “secretoma”, accurately regulating the proteins and growth factors secreted in the extracellular medium and having a relevant impact on different organs and systems within the human body.The trophic effects of ADSCs include stimulation of blood vessel formation, blood cells, gene transfer, and suppression of inflammation. In fact, ADSCs represent a source of several growth factors and cytokines that regulate the survival and differentiation of various cells and tissues.A large number of these molecules have been related to the innovative capacity of the ADSCs. It is not the purpose of this post to list all the cytokines that have already been isolated, so we limit ourselves to mention afew in the attached table.In conclusion, most of the factors secreted from ADSC act through mechanisms that mediate protection against cell death or, alternatively, induce cell migration and proliferation.In addition, they can act indirectly on target cells by promoting vascularization, with the consequent increase in oxygen and nutrient transport in affected areas, which in turn can promote local innovative processes.

Immunomodulatory function:

The immunomodulatory properties of ADSC and MSC have attracted interest as a unique property of these cells that can and should, we think, be harnessed for novel therapeutic approaches in autoimmune diseases.Mesenchymal Renew® treatment have been shown to inhibit the proliferation of both in vitro and in vivo activated T cells, but they stimulate the proliferation of regulatory T cells.Mesenchymal Renew® treatment are also known to be weakly immunogenic and to exert immunosuppressive effects on B cells, Natural killer cells, dendritic cells and neutrophils through various mechanisms.In addition, intravenous administration of allogeneic mesenchymal Renew® treatment has shown a marked suppression of host immune reactions in animal models of organ transplant rejection and in various autoimmune and inflammatory diseases.Some clinical trials using human mesenchymal Renew® treatment have also produced promising results in patients with graft-versus-host disease and autoimmune diseases.

Dr. Maria Luque del mar

Medical Director

Dr. Luque is a prestigios specialist with more than 20 years of experience in regenarative & aesthetic medicine.She is an expert in Renew treatment derived from fat. Outstanding curriculum in medicine & research ‘Cum Laude’ by the University of Malaga & in Sweden.